194 related articles for article (PubMed ID: 14870961)
1. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Meaney AM; O'Keane V
J Psychopharmacol; 2003 Dec; 17(4):455-8. PubMed ID: 14870961
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
O'Keane V
J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.
Meaney AM; Smith S; Howes OD; O'Brien M; Murray RM; O'Keane V
Br J Psychiatry; 2004 Jun; 184():503-8. PubMed ID: 15172944
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables.
Meaney AM; O'Keane V
Schizophr Res; 2007 Jul; 93(1-3):136-43. PubMed ID: 17467954
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density.
Stubbs B
J Psychiatr Ment Health Nurs; 2009 Nov; 16(9):838-42. PubMed ID: 19824978
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
O'Keane V; Meaney AM
J Clin Psychopharmacol; 2005 Feb; 25(1):26-31. PubMed ID: 15643097
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
Haddad PM; Wieck A
Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
[TBL] [Abstract][Full Text] [Related]
8. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.
De Hert M; Detraux J; Stubbs B
Expert Opin Drug Saf; 2016 Jun; 15(6):809-23. PubMed ID: 26986209
[TBL] [Abstract][Full Text] [Related]
9. Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
Lawford BR; Barnes M; Connor JP; Heslop K; Nyst P; Young RM
J Psychopharmacol; 2012 Feb; 26(2):324-9. PubMed ID: 21262859
[TBL] [Abstract][Full Text] [Related]
10. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
11. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Tollin SR
J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
[TBL] [Abstract][Full Text] [Related]
12. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
13. Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Kinon BJ; Liu-Seifert H; Stauffer VL; Jacob J
Clin Schizophr Relat Psychoses; 2013 Oct; 7(3):115-23. PubMed ID: 23395836
[TBL] [Abstract][Full Text] [Related]
14. [Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].
Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1173-84. PubMed ID: 16526183
[TBL] [Abstract][Full Text] [Related]
15. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
Riecher-Rössler A; Schmid C; Bleuer S; Birkhäuser M
Neuropsychiatr; 2009; 23(2):71-83. PubMed ID: 19573500
[TBL] [Abstract][Full Text] [Related]
16. Re: Prolactin levels and adverse events in patients treated with risperidone.
Denisov MF
J Clin Psychopharmacol; 2002 Oct; 22(5):538-40; author reply 540-1. PubMed ID: 12352286
[No Abstract] [Full Text] [Related]
17. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
Misra M; Papakostas GI; Klibanski A
J Clin Psychiatry; 2004 Dec; 65(12):1607-18; quiz 1590, 1760-1. PubMed ID: 15641865
[TBL] [Abstract][Full Text] [Related]
18. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.
Smith S; Wheeler MJ; Murray R; O'Keane V
J Clin Psychopharmacol; 2002 Apr; 22(2):109-14. PubMed ID: 11910254
[TBL] [Abstract][Full Text] [Related]
19. Prolactin awareness: an essential consideration for physical health in schizophrenia.
Montejo AL
Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
[TBL] [Abstract][Full Text] [Related]
20. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
